Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis

NCT01638520 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis, Pulmonary

Interventions

DRUG: Pascolizumab
DRUG: Placebo

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]